Tango Therapeutics, Inc. filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on August 11, 2026, covering the fiscal quarter ended June 30, 2026.

Key Highlights

  • Share count: As of August 4, 2026, the company had 168,610,367 shares of common stock outstanding, at a par value of $0.001 per share.
  • No product revenue: According to the filing, the company has not generated any revenue from product sales and has no products approved for commercial sale.
  • Continued losses: The filing states the company has incurred significant net losses since inception and anticipates continuing to incur losses for the foreseeable future.
  • Filer status: The company is classified as a non-accelerated filer and a smaller reporting company.
  • Supply concentration risk: The filing discloses that an affiliate of WuXi AppTec is the sole source of API for all of the company's clinical-stage product candidates.
  • Capital needs: The filing states the company will need to raise substantial additional funding, and that failure to do so could force delays, reductions, or elimination of product development programs.

Tango Therapeutics Q2 2026: Operations, Risks, and Pipeline Status

Tango Therapeutics, Inc. (NASDAQ:TNGX), a precision oncology company headquartered at 201 Brookline Ave., Suite 901, Boston, MA 02215, filed its quarterly report for the period ended June 30, 2026. The filing was submitted under Commission File Number 001-39485. The company describes itself as having a limited operating history and no approved products, and the filing confirms that no product sales revenue has been generated to date.

The filing highlights several operational and financial risks. The company disclosed that it anticipates operating losses will continue and that its operating results are expected "to fluctuate significantly in the future as our business advances." Raising additional capital, the filing notes, "may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates." The company also disclosed that it has never successfully completed any clinical trials, and certain programs remain in preclinical development.

A supply chain risk is specifically called out: the filing states that an affiliate of WuXi AppTec is the sole source of active pharmaceutical ingredient (API) for all clinical-stage product candidates. The filing further notes that WuXi AppTec "has been the subject of proposed Congressional legislation that, if enacted, could materially restrict our ability to conduct business with, and obtain API from, WuXi AppTec." The company also discloses reliance on a limited number of third parties for clinical trial conduct and drug manufacturing.

What Was Disclosed

Tango Therapeutics filed a Form 10-Q for the quarter ended June 30, 2026, disclosing 168,610,367 shares outstanding as of August 4, 2026, continued net losses, no product revenue, and material risks including sole-source API supply dependency and capital funding requirements.